A 12-week open trial of fluoxetine in 61 obsessive-compulsive disorder patients significantly improved depressive and obsessive-compulsive symptoms. Baseline depression scores were not related to improvement on two obsessive-compulsive scales. The results reinforce the hypothesis of serotonergic abnormalities in obsessive-compulsive disorder.